Transurethral surgical treatment of invasive bladder tumors (T1 and T2)
Wolf, H.; Iversen, H.G.; Olsen, P.R.; Højgaard, K.; Schroeder, T.
Ugeskrift for Laeger 149(48): 3247-3250
1987
ISSN/ISBN: 0041-5782 PMID: 3433525 Document Number: 293287
Ninety-nine primary transitional cell bladder tumours of categories T1 or T2 were treated by transurethral resection. 25% of these patients developed true recurrence indicating that surgery failed to control the tumour locally. These patients had a five-year survival of 20%. We suspect that many of them did not have local disease when treated. 25% of the total patient population did not develop new tumours within five years. They were cured by the first transurethral resection. 30% of the patients experienced new non-invasive tumour growth which could be managed by repeated resection. These two groups of patients did extremely well, since the five-year survival was equivalent to the five-year survival of a sex and age matched control population. Thus, more than 50% of the patients benefitted from transurethral surgery. Less than 20% experienced new invasive tumour growth. They are patients at risk of developing progressive bladder cancer disease. Five-year survival of these patients was about 50%. We conclude that the transitional cell bladder tumours of category T1 and some of category T2 are well treated by transurethral resection.